Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone

Diabetes

Volumn 49, Issue 4, 2000, Pages 539-547

  Camp, Heidi S ^a   Li, Ou ^a   Wise, Scott C ^a   Hong, Yu H ^a   Frankowski, Christy L ^a   Shen, Xi Qiang ^a   Vanbogelen, Ruth ^a   Leff, Todd ^a,b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE; TROGLITAZONE;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG RECEPTOR BINDING; GENE ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CELL; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; TRANSCRIPTION REGULATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 0034114625     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.49.4.539     Document Type: Article

References (36)

1. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
2. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
3. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
4. Tominaga M, Igarashi M, Daimon M, Eguchi H, Matsumoto M, Sekikawa A, Yamatani K, Sasaki H: Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocr J 40:343-349, 1993
5. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR-γ). J Biol Chem 270:12953-12956, 1995
6. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668, 1996
7. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, Lazar MA: A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. J Biol Chem 273:32679-32684, 1998
8. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A: Crystal structure of the ligand binding domain of the human nuclear receptor PPAR-γ. J Biol Chem 273:31108-31112, 1998
9. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW: Analysis of estrogen receptor function in vitro reveals three distinct classes of anti-estrogens. Mol Endocrinol 9:659-669, 1995
10. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP: Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21-30, 1994
11. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Chang CY, Ballas LM, Hamilton PT, McDonnell DP, Fowlkes DM: Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci U S A 96:3999-4004, 1999
12. Wagner BL, Pollio G, Leonhardt S, Wani MC, Lee DY, Imhof MO, Edwards DP, Cook CE, McDonnell DP: 16 alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. Proc Natl Acad Sci U S A 93:8739-8744, 1996
13. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937, 1998
14. Graves RA, Tontonoz P, Spiegelman BM: Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression [published erratum appears in Mol Cell Biol 12:3313, 1992]. Mol Cell Biol 12:1202-1208, 1992
15. Rubin CS, Hirsch A, Fung C, Rosen OM: Development of hormone receptors and hormonal responsiveness in vitro: insulin receptors and insulin sensitivity in the preadipocyte and adipocyte forms of 3T3-L1 cells. J Biol Chem 253:7570-7578, 1978
16. Cheng X, Reginato MJ, Andrews NC, Lazar MA: The transcriptional integrator CREB-binding protein mediates positive cross talk between nuclear hormone receptors and the hematopoietic bZip protein p45/NF-E2. Mol Cell Biol 17:1407-1416, 1997
17. Camp HS, Whitton AL, Tafuri SR: PPAR-gamma activators down-regulate the expression of PPAR-gamma in 3T3-L1 adipocytes. FEBS Lett 447:186-190, 1999
18. Ribon V, Johnson JH, Camp HS, Saltiel AR: Thiazolidinediones and insulin resistance: peroxisome proliferator activated receptor gamma activation stimulates expression of the CAP gene. Proc Natl Acad Sci U S A 95:14751-14756, 1998
19. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G: Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 47:810-814, 1998
20. Glass CK, Rose DW, Rosenfeld MG: Nuclear receptor coactivators. Curr Opin Cell Biol 9:222-232, 1997
21. Moras D, Gronemeyer H: The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol 10:384-391, 1998
22. Zhu Y, Qi C, Calandra C, Rao MS, Reddy JK: Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. Gene Expr 6:185-195, 1996
23. Gelman L, Zhou G, Fajas L, Raspe E, Fruchart JC, Auwerx J: p300 interacts with the N- and C-terminal part of PPAR-γ2 in a ligand-independent and -dependent manner, respectively. J Biol Chem 274:7681-7688, 1999
24. Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ, Leid M: p300 functions as a coactivator for the peroxisome proliferafor-activated receptor alpha. J Biol Chem 272:33435-33443, 1997
25. Kletzien RF, Clarke SD, Ulrich RG: Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41:393-398, 1992
26. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992
27. Love RR: Tamoxifen in axillary node-negative breast cancer: multisystem benefits and risks. Cancer Invest 10:587-593, 1992
28. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829-839, 1998
29. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, Reddy JK Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR-γ) gene: alternative promoter use and different splicing yield two mPPAR-γ isoforms. Proc Natl Acad Sci U S A 92:7921-7925, 1995
30. Fajas L, Fruchart JC, Auwerx J: PPAR-γ3 mRNA: a distinct PPAR-γ mRNA sub-type transcribed from an independent promoter. FEBS Lett 438:55-60, 1998
31. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR-gamma 2, a lipid-activated transcription factor. Cell 79:1147-1156, 1994
32. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 91:7355-7359, 1994
33. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82, 1998
34. Mansen A, Guardiola-Diaz H, Rafter J, Branting C, Gustafsson JA: Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 222:844-851, 1996
35. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS: Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPAR-γ): differential activity of PPAR-γ1 and -2 isoforms and influence of insulin. J Biol Chem 272:20230-20235, 1997
36. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA: Interdomain communication regulating ligand binding by PPAR-gamma. Nature 396:377-380, 1998